ICER's Gaze Turns to COVID Vaccine, Treatment Prices
The Institute for Clinical and Economic Review (ICER) is jumping into the fray of putting a price on what the world is waiting for — a safe, effective COVID-19 vaccine.
It published a white paper yesterday titled "Alternative Policies for Pricing Novel Vaccines and Drug Therapies for COVID-19" (treatment is mentioned but the focus is on vaccines).
Later this month and in early August, the Boston-based cost-effectiveness group is hosting a three-part online colloquium on the same topic. Peter Bach, Steve Miller, David Mitchell, and Aaron Kesselheim are scheduled to participate.
The white paper, written by Steven Pearson, ICER president, and Sarah Emond, the group's executive vice president, outlines six possible approaches to pricing a vaccine: unrestricted (which the white paper says is the status quo), cost-recovery, value-based, monetary prizes, compulsory licensing, and advanced market commitments.
Price has already entered the picture for antiviral treatments of COVID-19. Earlier this week, Gilead priced a five-day course of its antiviral, remdesivir, at $3,120 for patients with private insurance. Based on several assumptions, including a mortality benefit, an ICER report had benchmarked the price at $4,580-$5,080, although if remdesivir is used with dexamethasone, the ICER said benchmark should be dropped to $2,520-$2,800. In a prepared after Gilead announced the price, ICER said it wa a responsibe decision and "a promising sign for pricing decisions of other treatments for COVID-19 on the horizon.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Opzelura May Reduce Need for Other Treatments in Atopic Dermatitis | AAD 2025
March 11th 2025Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics during the 12 months after treatment with the topical nonsteroidal, finds study at American Academy of Dermatology Association annual meeting.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Supporting Patients with Type 1 Diabetes Through Education, Technology and Transparency
March 10th 2025Arti Masturzo, M.D., chief medical officer of CCS, spoke with MHE in this third part of a video series to share how CCS helps patients with type 1 diabetes effectively use glucose monitors and insulin pumps by providing clear guidance and troubleshooting support, recognizing that even minor errors in management can have significant health consequences.
Read More
Melanoma Treatment Advances Now Crossing into Other Skin Cancers
March 10th 2025Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with advanced basal cell carcinoma, squamous cell carcinoma and Merkel cell carcinoma, which is a rare and aggressive type of skin cancer.
Read More
